Company Analysis
Sign in

AtaiBeckley Inc. (ATAI)

ATAI · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2025
Full chart Alerts Compare
Grade5.0
◀ Past 4.2● Present 5.4▶ Future 5.0
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$4.1M+1227.6%
Net income-$660M-342.2%
Earnings per share$-2.91-212.9%
Operating cash flow-$103M-24.5%
Cash$85.3M+210.1%
Debt$0.00-100.0%
Shareholders’ equity$222M+90.8%
Shares, diluted226.5M+41.4%
Return on equity-297.5%
The recordfrom its filings
Filings in 202687
Newest filingSep 21 · 15-12G
Annual reportMar 6, 2026
Quarterly reportAug 11, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$1.7M
Insider buys, 12 months$0.00
Patents granted33
Filer category<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
2425
As filed, in USD. Nothing here is a forecast.

News

Sep 21, 2026 · SEC EDGAR · Form 15-12G
Deregistration notice
Open the filing on sec.gov
Sep 11, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 11, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 11, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 11, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton ATAI · research, not advice